Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer

Journal of B.U.ON.

Volumn 19, Issue 3, 2014, Pages 742-748

  Zhang, Tao ^a   Zhang, Dong Ming ^b   Zhao, Da ^a   Hou, Xiao Ming ^a   Yang, Tian Ning ^a  

^a LANZHOU UNIVERSITY   (China)

^b Pingliang People's Hospital   (China)

Author keywords

Carcinoma; Non small cell lung; Osteopontin; Platinum based chemotherapy; Response

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; OSTEOPONTIN; PEMETREXED; PLATINUM DERIVATIVE; RECOMBINANT ENDOSTATIN; VINBLASTINE; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CORRELATION ANALYSIS; DATA ANALYSIS SOFTWARE; DISTANT METASTASIS; FEMALE; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; OSTEOPONTIN; PLATINUM; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84908451286     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Alimujiang S, Zhang T, Han ZG et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-Small-Cell Lung Cancer A Meta-Analysis of Randomized Controlled Trials. Asian Pac J Cancer Prev 2013;14: 2413-2419.
2. Gu YF, Zhang H, Su D et al. miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer. Chin Med J (Engl) 2013;126: 4435-4439.
3. Fisher MD, D'Orazio A. Phase II and HI trials: Comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). Clin Lung Cancer 2000;2: 21-22.
4. Sun BS, You J, Li Y et al. Osteopontin knockdown sup- presses non-small cell lung cancer cell invasion and metastasis. Chin Med J (Engl) 2013;126: 1683-1688.
5. Härtung F, Weber GR RNA blood levels of osteopontin splice variants are cancer markers. Springer plus 2013: 2: 110.
6. Huang J, Pan C, Hu H et al. Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PLoS One 2012; 7(10): E47901.
7. Mack PM, Redman MW, Kari Chansky K et al. Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non-Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003. J Clin Oncol 2008;26: 4771-4776.
8. Snitcovsky I, Leitão GM, Pasini FS et al. Plasma Osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2009;135: 807-811.
9. Han SS, Lee SJ, Kim WJ et al. Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer. Tuberc Respir Dis (Seoul) 2013; 75: 104-110.
10. Stemberger C, Matusan-IlijaS K, Avirovic M et al. Osteopontin is associated with decreased apoptosis and integrin expression in lung adenocarcinoma. Acta Histochem 2013;1281: 148-147.
11. Milivojevic M, Boskovic V, Atanackovic J et al. Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma. Eur J Gynaecol Oncol 2013;34: 83-85.
12. Yamaga M, Tsuji K, Miyatake K et al. Osteopontin level in synovial fluid is associated with the severity of joint pain and cartilage degradation after anterior cruciate ligament rupture. PLoS One 2012, 7(ll): E49014.
13. Li J, Yang GZ, Zhu ZM et al. Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry. Exp Ther Med 2012; 3: 621-624.
14. Rao G, Wang H, Li B et al. Reciprocal interactions between tumor-associated macrophages and CD44-pos-itive cancer cells via osteopontin/CD44 promote tu- morigenicity in colorectal cancer. Clin Cancer Res 2013;19: 785-797.
15. Elli M, Dagdemir A, Bozkurt C et al. Serum osteopontin and CD44 levels in lymphoreticular malignancies in children. Bratisl Lek Listy 2012;113: 534-538.
16. Qin LF, Wang WC, Fang H et al. Expression of NF-KB and osteopontin of synovial fluid of patients with knee osteoarthritis. Asian Pac J Trop Med 2013;6: 379-382.
17. Huan JL, Xing L, Qin XJ et al. Expression and clinical significance of osteopontin in calcified breast tissue. Asian Pac J Cancer Prev 2012;13: 5219-5223.
18. Matusan-Ilijas" K, Damante G, Fabbro D et al. Osteopontin expression correlates with nuclear factor-KB activation and apoptosis down regulation in clear cell renal cell carcinoma. Pathol Res Pract 2011: 207: 104-110.
19. Tsai WC, Tsai WC, Lee HS et al. Association between Osteopontin and EGFR Expression with Clinicopathological Parameters in Hepatocellular Carcinoma. Chin J Physiol 2012: 55: 412-420.
20. Qiu ZB, Xu H, Duan C et al. Osteopontin is required for angiotensin II-induced migration of vascular smooth muscle cells. Pharmazie 2012;67: 553-558.